- Home
- BNTX vs EQR Comparison
BNTX vs EQR Comparison
Compare BNTX & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTX | EQR |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5B | 24.3B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | BNTX | EQR |
|---|---|---|
| Price | $90.09 | $60.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $134.15 | $69.54 |
| AVG Volume (30 Days) | 1.1M | ★ 2.3M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.60% |
| EPS Growth | N/A | ★ 8.09 |
| EPS | N/A | ★ 2.94 |
| Revenue | N/A | ★ $2,701,075,000.00 |
| Revenue This Year | N/A | $4.33 |
| Revenue Next Year | $2.61 | $3.07 |
| P/E Ratio | ★ N/A | $20.52 |
| Revenue Growth | N/A | ★ 4.76 |
| 52 Week Low | $79.81 | $58.38 |
| 52 Week High | $124.00 | $72.65 |
Technical Indicators
Market Signals| Indicator | BNTX | EQR |
|---|---|---|
| Relative Strength Index (RSI) | 34.12 | 38.43 |
| Support Level | N/A | $59.04 |
| Resistance Level | $112.30 | $60.57 |
| Average True Range (ATR) | 3.26 | 1.24 |
| MACD | -2.03 | -0.40 |
| Stochastic Oscillator | 31.77 | 19.11 |
Price Performance
Historical ComparisonAbout BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 318 apartment communities with over 86,000 units and is developing three additional properties with 935 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.